SUPN Supernus Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SUPN

Price (delayed)

$33.62

Market cap

$1.83B

P/E Ratio

35.02

Dividend/share

N/A

EPS

$0.96

Enterprise value

$1.89B

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for ...

Highlights
Supernus Pharmaceuticals's revenue has increased by 11% YoY
The gross profit is up by 10% YoY
The stock's price to earnings (P/E) is 68% more than its 5-year quarterly average of 20.8 but 2.5% less than its last 4 quarters average of 35.9
The quick ratio has contracted by 34% YoY but it has grown by 16% from the previous quarter
The EPS has declined by 31% year-on-year and by 15% since the previous quarter
The company's net income fell by 29% YoY and by 14% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.supernus.com
Peers: UTHR BMY ABT JNJ

Key stats

What are the main financial stats of SUPN
Market
Shares outstanding
54.48M
Market cap
$1.83B
Enterprise value
$1.89B
Valuations
Price to earnings (P/E)
35.02
Price to book (P/B)
2
Price to sales (P/S)
2.73
EV/EBIT
30.59
EV/EBITDA
12.88
EV/Sales
2.82
Earnings
Revenue
$668.5M
EBIT
$61.67M
EBITDA
$146.45M
Free cash flow
$161.81M
Per share
EPS
$0.96
Free cash flow per share
$2.98
Book value per share
$16.77
Revenue per share
$12.29
TBVPS
$18.25
Balance sheet
Total assets
$1.79B
Total liabilities
$879.66M
Debt
$517.37M
Equity
$912.15M
Working capital
$151.8M
Liquidity
Debt to equity
0.57
Current ratio
1.21
Quick ratio
1.06
Net debt/EBITDA
0.38
Margins
EBITDA margin
21.9%
Gross margin
86.1%
Net margin
7.8%
Operating margin
7.4%
Efficiency
Return on assets
3%
Return on equity
6%
Return on invested capital
14.7%
Return on capital employed
5.8%
Return on sales
9.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SUPN stock price

How has the Supernus Pharmaceuticals stock price performed over time
Intraday
0.24%
1 week
-4.73%
1 month
-8.52%
1 year
22.48%
YTD
-5.75%
QTD
-7.2%

Financial performance

How have Supernus Pharmaceuticals's revenue and profit performed over time
Revenue
$668.5M
Gross profit
$575.75M
Operating income
$49.33M
Net income
$52.04M
Gross margin
86.1%
Net margin
7.8%
The company's operating margin fell by 40% YoY but it rose by 7% QoQ
The net margin is down by 36% year-on-year and by 14% since the previous quarter
SUPN's operating income is down by 34% YoY but it is up by 7% from the previous quarter
The company's net income fell by 29% YoY and by 14% QoQ

Growth

What is Supernus Pharmaceuticals's growth rate over time

Valuation

What is Supernus Pharmaceuticals stock price valuation
P/E
35.02
P/B
2
P/S
2.73
EV/EBIT
30.59
EV/EBITDA
12.88
EV/Sales
2.82
The stock's price to earnings (P/E) is 68% more than its 5-year quarterly average of 20.8 but 2.5% less than its last 4 quarters average of 35.9
The EPS has declined by 31% year-on-year and by 15% since the previous quarter
SUPN's price to book (P/B) is 26% less than its 5-year quarterly average of 2.7 and 4.8% less than its last 4 quarters average of 2.1
Supernus Pharmaceuticals's equity has increased by 10% YoY and by 2.9% QoQ
The P/S is 22% below the 5-year quarterly average of 3.5 and 2.5% below the last 4 quarters average of 2.8
Supernus Pharmaceuticals's revenue has increased by 11% YoY

Efficiency

How efficient is Supernus Pharmaceuticals business performance
The return on sales has declined by 43% year-on-year and by 10% since the previous quarter
SUPN's return on invested capital is up by 39% year-on-year and by 17% since the previous quarter
The company's return on equity fell by 34% YoY and by 15% QoQ
The return on assets has declined by 33% year-on-year and by 17% since the previous quarter

Dividends

What is SUPN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SUPN.

Financial health

How did Supernus Pharmaceuticals financials performed over time
Supernus Pharmaceuticals's total assets is 104% higher than its total liabilities
SUPN's current ratio is down by 40% year-on-year but it is up by 13% since the previous quarter
The quick ratio has contracted by 34% YoY but it has grown by 16% from the previous quarter
The debt is 43% smaller than the equity
The debt is up by 18% since the previous quarter and by 18% year-on-year
Supernus Pharmaceuticals's debt to equity has increased by 16% from the previous quarter and by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.